W7: HANDLING SURVIVAL DATA IN COST-EFFECTIVENESS ANALYSIS
نویسندگان
چکیده
منابع مشابه
Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations
Cost-effectiveness analyses (CEAs) alongside randomised controlled trials (RCTs) are increasingly designed to collect resource use and preference-based health status data for the purpose of healthcare technology assessment. However, because of the way these measures are collected, they are prone to missing data, which can ultimately affect the decision of whether an intervention is good value f...
متن کاملA Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials
Missing data are a frequent problem in cost-effectiveness analysis (CEA) within a randomised controlled trial. Inappropriate methods to handle missing data can lead to misleading results and ultimately can affect the decision of whether an intervention is good value for money. This article provides practical guidance on how to handle missing data in within-trial CEAs following a principled appr...
متن کاملErratum to: Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations
Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and i...
متن کاملTreatments for newly diagnosed advanced ovarian cancer: analysis of survival data and cost-effectiveness evaluation.
The main therapeutic options currently available for patients with newly diagnosed advanced ovarian cancer include: (i) cisplatin-based chemotherapy at conventional doses without paclitaxel, (ii) paclitaxel+cisplatin at conventional doses and (iii) high-dose chemotherapy with autologous hematopoietic rescue. After conducting a literature search to identify large-scale clinical trials based on t...
متن کاملTreatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation.
The main therapeutic options currently available to induce remission in newly diagnosed cases of multiple myeloma include: i) melphalan at conventional doses without concurrent administration of interferon; ii) melphalan at conventional dose combined with interferon; iii) autologous bone marrow transplantation (ABMT). We conducted an analysis of the survival data reported in five large-scale pu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 1999
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(11)70161-9